Novavax, Inc. (NVAX) is a Biotechnology company in the Healthcare sector, currently trading at $8.39. It has a SharesGrow Score of 81/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of NVAX = $32.02 (+281.6% from the current price, the stock appears undervalued). Analyst consensus target is NVAX = $15 (+72.8% upside).
Valuation: NVAX trades at a trailing Price-to-Earnings (P/E) of 3.1 (S&P 500 average ~25).
Financials: revenue is $1.1B, +7.4%/yr average growth. Net income is $440M, growing at +139.2%/yr. Net profit margin is 39.2% (strong). Gross margin is 93.7% (+50.2 pp trend).
Balance sheet: total debt is $249M with negative equity of -$128M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 2.13 (strong liquidity). Debt-to-assets is 21.1%. Total assets: $1.2B.
Analyst outlook: 17 / 23 analysts rate NVAX as buy (74%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 83/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 74/100 (Pass), Future 85/100 (Pass), Income 100/100 (Pass).
